Video

Emerging therapies in AMD management

Author(s):

OT Staff Reports

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Anat Loewenstein, MD, chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

See more AMD Awareness content here, here, and here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
ASRS 2025: Dropless vitrectomy with suprachoroidal triamcinolone-moxifloxacin
August 23rd 2025

ASRS 2025: Dropless vitrectomy with suprachoroidal triamcinolone-moxifloxacin

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
August 23rd 2025

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
August 23rd 2025

FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
August 23rd 2025

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Opthea parts with CEO, lays off over 80% of company
August 23rd 2025

Opthea parts with CEO, lays off over 80% of company

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
August 23rd 2025

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease

© 2025 MJH Life Sciences

All rights reserved.